Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

rsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase II clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... - The Fight Against Cancer Innovation Trust (FACIT) ... formation of Turnstone Biologics Inc. (Turnstone), a biotechnology ... harness the patient,s own immune system. ... Children,s Hospital of Eastern Ontario ... Institute for Cancer Research (OICR), the Ottawa Hospital ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... -- - New Massive Open Online Course ... the United States Medical Licensing Examination ... medical information products and services, announced today that it ... designed to help medical students prepare for the United ... and most daunting of the three exams medical students ...
(Date:5/4/2015)... 4, 2015   Sentrian ™, the Remote Patient ... with the Scripps Translational Science Institute (STSI) ... patients with chronic obstructive pulmonary disease (COPD), a chronic ... the nation,s third leading cause of death. The patients ... System , a wholly owned subsidiary of Anthem.   ...
Breaking Biology Technology:Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5
... the U.S. Department of Energy,s Argonne National Laboratory, will ... 138 on Nanoalloys: From Theory to Application, to be ... in the United Kingdom. , The Faraday Discussions are ... have been of enormous influence in reviewing the current ...
... Stevens Institute of Technology and NACE International, ... Section, will host the Winter 2007 Corrosion Symposium: ... Charles V. Schaefer, Jr. School of Engineering & ... Keith Sheppard, a professor materials engineering, will welcome ...
... splinting and bracing technology, ST. PAUL, ... of St. Paul, Minn., and Product Innovations, ... announce the launch of Exos Corporation, a ... innovative orthopedic,support devices. Exos will focus ...
Cached Biology Technology:Enova Medical Launches Exos Corporation 2
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... American Societies for Experimental Biology (FASEB) announces the opening ... of Cilia and Flagella. The 2013 Biology ... unique scientific conference where basic and translational research intersect ... and human ciliopathies. The underlying theme of the 2013 ...
... American Societies for Experimental Biology (FASEB) announces the ... (SRC): Mitochondrial Assembly and Dynamics in Health, Disease ... Assembly and Dynamics in Health, Disease and Aging ... diverse aspects of mitochondrial biology and dysfunction are ...
... 4, 2013) People tend to lose muscle mass ... or counteract age-related muscle loss. A study conducted by ... that current guidelines for meat consumption are based on ... preservation of muscle mass, particularly for older individuals who ...
Cached Biology News:
... the smallest electronic pressure controller available measuring ... configured this unit specifically for the analytical ... in carrier gas flow control, microfluidic flow ... hydro-dynamic focusing, the OEM-EPC offers external pressure ...
... Slide Table is designed for moving loads ... provides maximum force output while limiting overall ... of stainless steel ball bearings guided on ... self-compensating shock absorbers provide energy absorption and ...
... is obtained from non-demolished blood ... fasted donors. The donors are ... and are maintained on an ... Protein Concentration : 85 mg/ml ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
Biology Products: